Related Experiment Video

Updated: Jul 4, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

905

MASLD emerging from the fog of fatty liver

Giulio Marchesini1, Roberto Vettor2, Massimo Pinzani3

  • 1Universita' degli Studi di Bologna, Bologna, Italy.

Journal of Hepatology
|January 26, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.7K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.1K

Related Experiment Videos

Last Updated: Jul 4, 2025

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
07:03

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss

Published on: July 19, 2024

905
Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment
07:12

Author Spotlight: Analysis of Fluorescent-Stained Lipid Droplets with 3D Reconstruction for Hepatic Steatosis Assessment

Published on: June 2, 2023

6.7K
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
08:41

Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease

Published on: March 24, 2023

1.1K

Related Concept Videos

Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

540
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
540
Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

1.6K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
1.6K

Articles linked to this work by shared authors, journal, and citation graph.

Hepatology: Emerging Paradigms in MASLD, Viral Hepatitis, Cholestatic Liver Disease, Portal Hypertension and Hepatocellular Carcinoma: Summary of the First Annual Paris International Liver Meeting 2026.

Liver international : official journal of the International Association for the Study of the Liver·2026

Alcohol Plays a Detrimental Role in the Prognosis of Hepatocellular Carcinoma Related to Steatotic Liver Disease.

Liver cancer·2026

Ischemic preconditioning promotes hepatic differentiation in human liver organoids.

Frontiers in cell and developmental biology·2026

Brain health awareness among solid organ transplant candidates and recipients: a single centre survey.

BMC neurology·2026

An imbalance between CD80 and CD86 levels and CD4 regulatory T cell number and transendocytosis function exists in the liver in autoimmune hepatitis.

Clinical and experimental immunology·2026

Thyroid function and liver fibrosis: FT3 levels are inversely and independently correlated with enhanced liver fibrosis score in solid organ transplant patients with dysglycemia.

Frontiers in immunology·2026

Mouse models of acute and chronic hepatitis E virus infection.

Journal of hepatology·2026

Barriers to Viral Hepatitis Elimination and New Strategies to Overcome Them in Low- and Middle-Income Countries.

Journal of hepatology·2026

Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.

Journal of hepatology·2026

Artificial intelligence and personalised medicine in liver cancer.

Journal of hepatology·2026

Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.

Journal of hepatology·2026

Serum HBsAg cannot distinguish cccDNA activity from integrated HBV DNA expression in chronic hepatitis B virus infection.

Journal of hepatology·2026

The Femoral Impingement Index Predicts Inferior Clinical Outcomes in Men Undergoing Hip Arthroscopy for Femoroacetabular Impingement Syndrome.

Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association·2026

Marfan-Like Clinical Features in DLG4 (Discs Large MAGUK Scaffold Protein 4)-Related Synaptopathy: A Brazilian Case Report.

Cureus·2026

Endovascular embolization for intracranial mycotic aneurysms in left ventricular assist device patients: A case series.

JHLT open·2026

Periaortitis and Retroperitoneal Fibrosis in a Patient With a Normal IgG4 Level: A Case Report and Review of the Literature.

Cureus·2026

SKP2 Regulates Pulmonary Inflammatory Injury Triggered by Bacterial Infection Through p27-Mediated Degradation of FOXN3.

MedComm·2026

Complete recovery of thrombotic microangiopathy with severe acute kidney injury due to intravenous use of modified release oxycodone.

Clinical kidney journal·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us